DOI:
10.1039/C4RA06768A
(Paper)
RSC Adv., 2014,
4, 41521-41528
Lewis acid free synthesis of 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-triones promoted by 1,1,1,3,3,3-hexafluoro-2-propanol
Received
7th July 2014
, Accepted 20th August 2014
First published on 20th August 2014
Abstract
A convenient, environmentally friendly and efficient procedure for the synthesis 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione derivatives has been developed via multi-component and one-pot reactions of various aldehydes with cyclic 1,3-diketones and phthalhydrazide 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP). In simple and mild reaction conditions, the use of HFIP is explored as an easy workup and a green catalyst for the one-pot three-component synthesis of 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-triones. Thus, this practical method is developed as a notable medium for these derivatives via a multicomponent reaction.
Introduction
Multi-component reactions (MCRs) enable multiple reactions1 leading to interesting heterocyclic frameworks which are useful for the construction of poly-functionalized heterocyclic ‘drug like’ libraries.2,3 These reactions have been investigated widely in organic and diversely oriented syntheses. In the past few decades, the synthesis of novel heterocyclic compounds has received a great deal of attention, most notably for the construction of heterocyclic compounds.4,5 Nitrogen-containing heterocyclic compounds are widespread in nature, and their applications to pharmaceuticals, agrochemicals, and functional materials are becoming more and more important.6 3,4-Dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-triones which are important N-heterocycles, comprise a key structural unit of numerous natural and synthetic bioactive molecules.7 Moreover, fused phthalazines were found to possess multiple pharmacological and biological activities such as antimicrobial,8 antifungal,9 anticancer,10 anti-inflammatory,11 anticonvulsant,12 cardiotonic,13 and vasorelaxant.14 These target molecules could also be promising materials for new luminescence or fluorescence probes.15
Therefore, a number of methods have been reported for the synthesis of phthalazine derivatives. Nonetheless, the development of new synthetic methods for the proficient preparation of heterocycles containing the phthalazine ring fragment is an interesting challenge. In recent years, much attention has been directed toward synthesis of 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione derivatives. Synthesis of these derivatives has been reported using p-TSA,16 Me3SiCl,17 silica sulfuric acid,18 H2SO4,19 Mg(HSO4)2,20 and silica supported poly phosphoric acid,21 montmorillonite K-10,22 P38 MAP kinase,23 and N,N,N,N-tetramethylguanidinium acetate [TMG][Ac]24 as catalysts. Since many of these methods are associated with more disadvantages such as the use of an expensive catalyst or toxic organic solvents,17,20 strong acidic conditions,16,19 and harsh reaction conditions,16–21 synthetic methods should be designed to use substances that exhibit little or no toxicity to human health and the environment.
Results and discussion
In recent years, the fluorous solvents have attracted a grabbing attention and an increasing interest in the context of green reaction media, as catalyst and co-solvent (additive). Fluorinated alcohols were reported to possess lower boiling points and higher melting points than their non-fluorinated counterparts, high polarity, generally selective, without effluents, strong hydrogen bond donation properties and the ability to solvate water. Reactions in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) have a facile isolation of the product and can be easily recovered by distillation.25–27 HFIP has been used in organic synthesis because these fluorinated alcohols are available on a commercial scale. They can be well dispersed in the reaction mixtures in solvolysis reaction, where the generated cationic intermediates can be trapped by nucleophiles. Moreover, HFIP takes part in the reactions as both catalyst and solvent. The electron withdrawing character of CF3 confers high acidity to the hydrogen of the hydroxyl group.28 In addition this property, fluorinated alcohols are not nucleophiles or hydrogen bond acceptors. Thus, the degree of auto-association of fluorinated alcohols is low. The chief advantage of fluorinated alcohols, for instance hexafluoroisopropanol (HFIP) and trifluoroethanol (TFE), is the possibility to carry out, in the absence of promoting agents, reactions that usually require the aid of Lewis acids or catalysts.29,30
HFIP provides as a dominant hydrogen-bond donor, as was indicated not only by the spectral studies and calorimetric measurements, but also by the isolation of extremely stable complexes with a number of nucleophilic species.31 Compared to other solvents, HFIP (bp = 58 °C) are unique due to their high ionizing powers, strong hydrogen bond donor abilities, mild acidic characters (pKa = 12.4 and pKa = 9.3, respectively), and low nucleophilicity.32,33 In recent decades, approaches for the synthesis of biologically interesting products via multi-component reactions were developed. The challenge in this field was developing efficient and rapid green methods. Green chemistry approaches are most important due to the reduction in byproducts, a reduction in produced waste, and reduction of energy cost. In this report, based on earlier success in the preparation of heterocycles with nucleous nitrogen,34 we present the results of an extended investigation on the activity this solvent, as an efficient medium for the synthesis of 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-triones (Scheme 1).
![image file: c4ra06768a-s1.tif](/image/article/2014/RA/c4ra06768a/c4ra06768a-s1.gif) |
| Scheme 1 One-pot synthesis of 1H-indazolo[1,2-b]phthalazine-triones. | |
We decided to explore the possibility of a simple and facile synthesis 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione derivatives by a three-component condensation reaction of cyclic 1,3-diketones, aromatic aldehydes and phthalhydrazide in the presence of HFIP as a novel and reusable solvent.
First, we examined the amount of HFIP and the reaction temperature using dimidone (1 mmol), benzaldehyde (1 mmol) and phthalhydrazide (1 mmol) to the consequent 3,3-dimethyl-13-phenyl-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione was studied under reaction conditions in the presence of HFIP at different temperatures and amount of HFIP. The best results were achieved in 0.3 ml at 55 °C. No product was observed in the absence of HFIP at 55 °C after one day.
Based on the optimized reaction conditions, a range of 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione derivatives was synthesized by the reaction of cyclic 1,3-diketones, aldehyde and phthalhydrazide (Table 1). The structures of the products were established from their spectral properties (1H NMR, 13C NMR and elemental analysis) and also by comparison with available literature data.
Table 1 Synthesis of 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione derivatives using HFIP
As shown in Table 1, the direct multi-component reactions worked fit with a variety of aldehydes together with those bearing electron-withdrawing and electron-donating groups such as Me, OMe, Cl, F, Br or NO2, and the target molecules were obtained in high to excellent yields.
In continuation of our studies in this field, we decided to synthesize 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-triones in shorter times and better yields with HFIP. The reaction between 4-fluorobenzaldehydes (1.0 mmol), dimedone (1.0 mmol) with phthalhydrazide (1 mmol) was carried out with HFIP (0.5 ml) at 55 °C. The target molecule (4f) of this reaction was obtained with 90% of yield in 15 h.
Trifluoroethanol (TFE) is a solvent with similar physicochemical properties of 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP). In order to examine the catalytic activity of TFE in this reaction, benzaldehyde (1.0 mmol), dimedone (1.0 mmol) with phthalhydrazide (1 mmol) and TFE (0.3 ml) was selected as the model at 70 °C. After 8 h, only 78% of expected 3,3-dimethyl-13-phenyl-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4a) was obtained.
The formation of strong hydrogen bonds with C
O groups facilitates all reaction routes. In this process, HFIP with a strong H-bond donor (α = 1.96, pKa = 9.3), high ionizing power (YOTs = 3.79), and polarity (Ps = 11.08) could activate the C
O groups and play a significant role in increasing the electrophilic character.25–27 Therefore, The formation of products 4a–p can be rationalized by initial formation of heterodiene by standard Knoevenagel condensation of cyclic 1,3-diketones and aromatic aldehydes in the presence of a catalytic amount. Subsequent Michael-type addition of phthalhydrazide to the heterodienes followed by cyclization and dehydration afford the corresponding products 4a–p (Scheme 2).
![image file: c4ra06768a-s2.tif](/image/article/2014/RA/c4ra06768a/c4ra06768a-s2.gif) |
| Scheme 2 Proposed mechanism. | |
To recognize the capability of the present method in comparison with reported methods for the preparation of 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione derivatives, the model reaction of dimedone, benzaldehyde and phthalhydrazide was studied in the literature. Their results clearly demonstrate that HFIP is efficient for this three-component reaction (Table 2).
Table 2 Comparison of methods for the synthesis of 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-triones
Entry |
Compounds 4 |
Conditions |
Time (h) |
Yield (%) |
1 |
![image file: c4ra06768a-u17.tif](/image/article/2014/RA/c4ra06768a/c4ra06768a-u17.gif) |
PMA–SiO2/solvent-free/80 °C (ref. 17) |
0.66 |
85 |
[bmim]BF4/H2O–EtOH/reflux20 |
0.58 |
88 |
1-Butyl-3-methylimidazolium bromide/ultrasound19 |
0.25 |
90 |
HFIP/55 °C |
8 |
92 |
2 |
![image file: c4ra06768a-u18.tif](/image/article/2014/RA/c4ra06768a/c4ra06768a-u18.gif) |
[bmim]BF4/H2O–EtOH/reflux20 |
0.5 |
92 |
Silica–SO3H/solvent-free/125 °C (ref. 19a) |
0.11 |
85 |
Sulfuric acid-modified/solvent-free/80 °C (ref. 19b) |
0.25 |
90 |
HFIP/55 °C |
10 |
92 |
3 |
![image file: c4ra06768a-u19.tif](/image/article/2014/RA/c4ra06768a/c4ra06768a-u19.gif) |
PMA–SiO2/solvent-free/80 °C (ref. 17) |
0.66 |
82 |
Sulfuric acid-modified/solvent-free/80 °C (ref. 19) |
1.16 |
50 |
HFIP/55 °C |
9 |
82 |
The reusability of the catalyst was checked by separating HFIP from mixture and reuse in subsequent reactions. The recovered HFIP can be reused for at least three additional times in subsequent reactions with 92, 90 and 84% of yields in 8 h for 4a without significant loss in product yield.
Experimental
Chemicals were obtained from Merck and Fluka. IR spectra were recorded on a Shimadzu 435-U-04 spectrophotometer (KBr pellets). 1H NMR spectra were obtained using a Jeol FT NMR 300 MHz spectrometer in CDCl3 using TMS as an internal reference. Melting points were determined in open capillary tubes in a Stuart BI Branstead Electrothermal Cat no.: IA92003 apparatus and are uncorrected. Mass spec techniques were conducted in GCMS-QP1100EX.
General procedure for the synthesis of 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-triones (4a–p)
To a mixture of various aldehydes (1.0 mmol), dimedone or 1,3 cyclohexadione (1.0 mmol) with phthalhydrazide (1 mmol) and HFIP (0.3 ml) was stirred magnetically at 55 °C for an appropriate time as mentioned in Table 1. After completion of the reaction (monitored by TLC; n-hexane/ethylacetate, 4/1), the reaction mixture was diluted with EtOH (96%, 0.1 ml) and stirred for 2 min in 55 °C. Next, the resulting crude product was poured into crushed ice and the solid product, which separated was filtered, recrystallized from ethanol (96%, 3 ml) to get pure 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-triones (4a–p). Then, the HFIP was separated by distillation and reused in the next run.
3,3-Dimethyl-13-phenyl-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4a). Yellow powder, mp: 200–202 °C, (206–208 °C);17 IR (KBr, cm−1): 2958, 1661, 1575; 1H NMR (300 MHz, CDCl3, ppm) δ 1.23 (6H, s, 2Me), 2.35 (2H, s, CH2CO), 3.26 and 3.44 (2H, AB system, J = 18.6 Hz, CHaHbCO), 6.47 (1H, s, CHN), 7.33–8.37 (9H, m, Ph); 13C NMR (75 MHz, CDCl3, ppm) δ 28.5, 28.7, 34.7, 38.1, 50.9, 64.9, 118.6, 127.1, 127.7, 127.9, 128.7, 128.9, 129.1, 133.6, 134.5, 136.4, 150.9, 154.3, 156.1, 192.2; MS, m/z (%): 372 (M, 15), 295 (100), 104 (84), 76 (67).
3,3-Dimethyl-13-(4-methoxyphenyl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4b). Yellow powder, mp: 207–209 °C, (207–209 °C);17 IR (KBr, cm−1): 2958, 1663, 1628, 1604, 1513, 1465, 1425, 1361,1312, 1265, 1242, 1172, 1099, 1027, 842, 797, 699; 1H NMR (300 MHz, CDCl3, ppm) δ 8.25–8.35 (m, 2H), 7.82–7.85 (m, 2H), 6.84–7.35 (m, 4H), 6.42 (s, 1H), 3.76 (s, 3H), 3.23 and 3.42 (2H, AB system, J = 19.2 Hz), 2.34 (s, 2H), 1.21 (s, 6H); 13C NMR (75 MHz, CDCl3, ppm) δ 192.23, 159.74, 156.07, 154.28, 150.75, 134.47, 133.47, 129.18, 128.98, 128.51, 128.36, 127.93, 127.71, 118.58, 114.14, 64.59, 55.21, 50.99, 38.07, 34.65, 28.71, 28.51; MS, m/z (%): 402.
3,3-Dimethyl-13-(4-nitrophenyl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4c). Yellow powder, mp: 226–228 °C, (224–225 °C);20 IR (KBr, cm−1): 2924, 1695, 1659, 1615; 1H NMR (300 MHz, CDCl3, ppm) δ 1.21 (3H, s, Me), 1.23 (3H, s, Me), 2.33 and 2.38 (2H, AB system, J = 16.5 Hz, CHaHbCO), 3.26 and 3.43 (2H, AB system, J = 19.2 Hz, CHaHbCO), 6.52 (1H, s, CHN), 7.61–8.41 (8H, m, Ph); 13C NMR (75 MHz, CDCl3, ppm) δ 28.4, 28.7, 34.7, 38.0, 50.8, 64.2, 117.3, 124.1, 127.8, 128.1, 128.3, 128.6, 128.9, 133.9, 134.9, 143.4, 147.9, 151.7, 154.6, 155.9, 192.1; MS, m/z (%): 417 (M, 5), 295 (100), 104 (48), 76 (75).
3,3-Dimethyl-13-(4-chlorophenyl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4d). White powder, mp: 263–265 °C, (260–262 °C);20 IR (KBr, cm−1): 2957, 1656, 1623; 1H NMR (300 MHz, CDCl3, ppm) δ 1.22 (3H, s, Me), 1.23 (3H, s, Me), 2.35 (2H, s, CH2CO), 3.25 and 3.43 (2H, AB system, J = 19.1 Hz, CHaHbCO), 6.43 (1H, s, CHN), 7.31–8.39 (8H, m, Ph); 13C NMR (75 MHz, CDCl3, ppm) δ 28.5, 28.7, 34.7, 38.0, 50.9, 64.3, 118.1, 127.7, 128.1, 128.5, 128.8, 128.9, 129.0, 133.7, 134.5, 134.6, 134.9, 151.1, 154.3, 156.0, 192.2 ppm; MS, m/z (%): 406 (M, 5), 295 (100), 104 (43), 76 (46).
3,3-Dimethyl-13-(3-nitrophenyl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4e). Yellow powder, mp: 270–272 °C, (270–272 °C);17 IR (KBr, cm−1): 2926, 1660, 1625; 1H NMR (300 MHz, CDCl3, ppm) δ 1.12 (6H, s, 2Me), 2.27 (2H, s, CH2CO), 3.23 (2H, br s, CH2CO), 6.46 (1H, s, CHN), 7.60–8.37 (8H, m, Ph); 13C NMR (75 MHz, CDCl3, ppm) δ 28.3, 28.9, 34.6, 38.2, 51.5, 64.2, 116.9, 127.3, 127.3, 128.4, 128.7, 129.2, 129.8, 131.5, 132.7, 133.1, 133.6, 134.5, 135.5, 151.8, 154.4, 156.4, 192.2; MS, m/z (%): 417 (M, 10), 295 (100), 104 (48), 76 (75).
3,3-Dimethyl-13-(4-methylphenyl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4g). Yellow powder, mp: 227–229 °C, (227–229 °C);17 IR (KBr, cm−1): 2956, 1663, 1621; 1H NMR (300 MHz, CDCl3, ppm) δ 1.23 (6H, s, 2Me), 2.30 (3H, s, CH3), 2.35 (2H, s, CH2CO), 3.24 and 3.43 (2H, AB system, J = 18.5 Hz, CHaHbCO), 6.43 (1H, s, CHN), 7.12–8.38 (8H, m, Ph); 13C NMR (75 MHz, CDCl3, ppm) δ 21.3, 28.5, 28.8, 34.7, 38.1, 50.9, 64.9, 118.7, 127.1, 127.7, 127.9, 128.9, 129.2, 129.5, 133.4, 133.5, 134.5, 138.5, 150.8, 154.2, 156.1, 192.2; MS, m/z (%): 386 (M, 10), 295 (100), 104 (45), 76 (46).
3,3-Dimethyl-13-(thiophen-2-yl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4h). Yellow powder, mp: 219–222 °C, (218–220 °C);23 IR (KBr, cm−1): 2958, 1661, 1575; 1H NMR (300 MHz, CDCl3, ppm) δ 1.22 (6H, s, 2Me), 2.31 (2H, s, CH2CO), 3.19 and 3.35 (2H, AB system, J = 18.6 Hz, CHaHbCO), 6.48 (1H, s, CHN), 7.29–8.35 (7H, m, Ar); 13C NMR (75 MHz, CDCl3, ppm) δ 28.6, 28.7, 34.7, 38.0, 50.9, 64.9, 118.6, 127.1, 127.7, 127.9, 128.7, 128.9, 129.1, 133.6, 134.5, 136.4, 150.9, 154.3, 156.0, 192.1; MS, m/z (%): 372 (M, 15), 295 (100).
13-(Phenyl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4i). Yellow powder, mp: 223–225 °C, (223–225 °C);20 IR (KBr, cm−1): 2954, 1659, 1623, 1366, 1304, 1267, 702; 1H NMR (300 MHz, CDCl3, ppm) δ 8.24–8.36 (m, 2H), 7.82–7.85 (m, 2H), 7.31–7.43 (m, 5H), 6.44 (s, 1H), 3.29–3.60 (m, 2H), 2.44–2.62 (m, 2H), 2.23–2.27 (m, 2H); 13C NMR (75 MHz, CDCl3 ppm) δ 192.50, 156.01, 154.21, 152.29, 144.35, 136.33, 134.51, 133.52, 129.04, 128.65, 128.07, 127.95, 127.69, 119.64, 64.94, 36.89, 24.47, 22.26; MS, m/z (%): 344.
13-(4-Hydroxyphenyl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4l). White powder, mp: 267–269 °C, (265–266 °C);20 IR (KBr, cm−1): 3424, 2899, 1642, 1612, 1371, 1310, 1279 703; 1H NMR (300 MHz, CDCl3, ppm) δ 8.83 (s, 1H), 8.23–8.35 (m, 2H), 7.83–7.86 (m, 2H), 7.23 (d, 2H, J = 8.7 Hz), 6.78 (d, 2H, J = 8.4 Hz), 6.37 (s, 1H), 3.35–3.60 (m, 2H), 2.46–2.47 (m, 2H), 2.24–2.28 (m, 2H); 13C NMR (75 MHz, CDCl3, ppm) δ 197.29, 162.42, 160.57, 158.79, 157.08, 139.25, 138.28, 137.07, 133.73, 133.38, 132.66, 132.09, 131.80, 130.27, 124.18, 120.28, 69.25, 41.68, 29.16, 27.02; MS, m/z (%): 360.
13-(4-Methoxyphenyl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4m). Yellow powder, mp: 245–247 °C, (242–244 °C);17 IR (KBr, cm−1): 2950, 1657, 1624, 1365, 1306, 1246, 703; 1H NMR (300 MHz, CDCl3, ppm) δ 8.25–8.35 (m, 2H), 7.82–7.86 (m, 2H), 7.32–7.37 (m, 2H), 6.83–6.87 (m, 2H), 6.42 (s, 1H), 3.75 (s, 3H), 3.28–3.60 (m, 2H), 2.44–2.49 (m, 2H), 2.23–2.30 (m, 2H); 13C NMR (75 MHz, CDCl3, ppm) δ 192.60, 159.73, 156.05, 154.22, 152.19, 134.48, 133.47, 129.16, 128.94, 128.55, 128.30, 127.93, 127.69, 119.65, 114.09, 64.58, 55.23, 36.96, 24.51, 22.34; MS, m/z (%): 374.
13-(3-Nitrophenyl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4n). Yellow powder, mp: 232–234 °C, (228–230 °C);20 IR (KBr, cm−1): 2926, 1662, 1624, 1369, 1305, 1285, 697; 1H NMR (300 MHz, CDCl3, ppm) δ 8.22–8.40 (m, 2H), 8.14–8.17 (m, 2H), 7.52–7.92 (m, 4H), 6.52 (s, 1H), 3.31–3.65 (m, 2H), 2.46–2.50 (m, 2H), 2.23–2.38 (m, 2H); 13C NMR (75 MHz, CDCl3, ppm) δ 192.46, 164.62, 155.99, 154.65, 153.21, 148.53, 138.60, 134.78, 129.62, 128.27, 127.76, 123.69, 121.70, 118.26, 64.25, 36.79, 24.54, 22.23; MS, m/z (%): 389.
13-(4-N,N-Dimethylphenyl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4o). White powder, mp: 257–259 °C, (256–258 °C);20 IR (KBr, cm−1): 2923, 1661, 1616, 1364, 1305,1280, 699; 1H NMR (300 MHz, CDCl3, ppm) δ 8.25–8.34 (m, 2H), 7.80–7.83 (m, 2H), 7.26–7.29 (m, 2H), 6.63–6.66 (m, 2H), 6.40 (s, 1H), 3.35–3.61 (m, 2H), 2.89 (s, 6H), 2.46–2.48 (m, 2H), 2.24–2.28 (m, 2H); 13C NMR (75 MHz, CDCl3, ppm) δ 192.59, 156.12, 154.12, 151.89, 150.64, 134.34, 133.28, 129.39, 128.98, 128.92, 128.21, 127.84, 127.70, 123.41, 119.95, 112.40, 112.26, 64.83, 40.64, 40.36, 37.02, 24.53, 22.39; MS, m/z (%): 387.
13-(Naphthalen-2-yl)-3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-trione (4p). Yellow powder, mp: 248–250 °C, (248–250 °C);19b IR (KBr, cm−1): 2961, 1655, 1626; 1H NMR (300 MHz, CDCl3, ppm) δ 1.22 (6H, s, 2Me), 2.33 (2H, s, CH2C), 3.24–3.50 (2H, AB system, J = 18.6 Hz, CHaHbCO), 6.62 (1H, s, CHN), 7.45–8.38 (11H, m, Ph); 13C NMR (75 MHz, CDCl3, ppm); δ 28.4, 28.7, 34.6, 38.1, 50.9, 65.1, 118.6, 124.2, 126.2, 126.3, 126.8, 127.6, 127.7, 127.9, 128.2, 128.7, 129.0, 129.6, 133.2, 133.4, 133.5, 133.6, 134.5, 150.8, 154.2, 156.1, 192.1; MS, m/z (%): 422 (M, 5), 295 (100), 104 (40), 76 (56).
Conclusion
In summary, a novel and highly efficient methodology for the synthesis of 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-triones by a three-component condensation reaction of cyclic 1,3-diketones, aromatic aldehydes and phthalhydrazide in the presence of HFIP was reported. In contrast to the existing methods using potentially hazardous catalysts/additives, this new method offers the following competitive advantages such as avoiding the use of any base, metal, or Lewis acid catalysts. To the best of our knowledge, this method represents the first example of the synthesis 3,4-dihydro-1H-indazolo[1,2-b]phthalazine-1,6,11(2H,13H)-triones in the absence of catalyst.
Acknowledgements
This research work was supported by the University of Hakim Sabzevari. Authors wish to thank the University of Hakim Sabzevari for financial support to carry out this research.
References
-
(a) B. Maleki, M. Gholizadeh and Z. Sepehr, Bull. Korean Chem. Soc., 2011, 32, 1697 CrossRef CAS;
(b) B. Maleki, S. Barzegar, Z. Sepehr, M. Kermanian and R. Tayebee, J. Iran. Chem. Soc., 2012, 9, 757 CrossRef CAS PubMed;
(c) M. J. Climent, A. Corma and S. Iborra, RSC Adv., 2012, 2, 16 CAS;
(d) J. Cai, J. Huang, C. M. Li, H. Feng and Z. Liu, RSC Adv., 2013, 3, 18661 RSC;
(e) Y. Qu, W. Zhou, L. Jiang and H. Fu, RSC Adv., 2013, 3, 18305 RSC;
(f) S. H. Shuit, K. F. Yee, K. T. Lee, B. Subhash and S. H. Tan, RSC Adv., 2013, 3, 9070 RSC.
-
(a) K. Mogilaiah, D. C. Chowdary and R. B. Rao, Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem., 2001, 40, 43 Search PubMed;
(b) Y. L. Chen, K. G. Fang, J. Y. Sheu, S. L. Hsu and C. C. Tzeng, J. Med. Chem., 2001, 44, 2374 CrossRef CAS PubMed.
-
(a) J. Elguero, in Comprehensive Heterocyclic Chemistry, ed. A. R. Katritzky, C. W. Rees and E. F. V. Scriven, Pergamon, Oxford, 1996, vol. 3, p. 1 Search PubMed;
(b) B. Willy and T. J. Muller, Eur. J. Org. Chem., 2008, 4157 CrossRef CAS PubMed.
-
(a) W. R. Vaughan, Chem. Rev., 1948, 43, 447 CrossRef CAS;
(b) R. A. Clement, J. Org. Chem., 1960, 25, 1724 CrossRef CAS;
(c) H. W. Heine, R. Henrie, L. Heitz and S. R. Kovvali, J. Org. Chem., 1974, 39, 3187 CrossRef CAS.
-
(a) F. Al-Assar, K. N. Zelenin, E. E. Lesiovskaya, I. P. Bezhan and B. A. Chakchir, Pharm. Chem. J., 2002, 36, 598 CrossRef CAS;
(b) R. P. Jain and J. C. Vederas, Bioorg. Med. Chem. Lett., 2004, 14, 3655 CrossRef CAS PubMed.
- V. P. Litvinov, Russ. Chem. Rev., 2003, 72, 69 CrossRef CAS PubMed.
- G. Shukla, R. K. Verma, G. K. Verma and M. S. Singh, Tetrahedron Lett., 2011, 52, 7195 CrossRef CAS PubMed.
- R. W. Carling, K. W. Moore, L. J. Street, D. Wild, C. Isted, P. D. Leeson, S. Thomas, D. O'Connor, R. M. Mckernan, K. Quirk, S. M. Cook, J. R. Atack, K. A. Wafford, S. A. Thompson, G. R. Dawson, P. Ferris and J. L. Castro, J. Med. Chem., 2004, 47, 1807 CrossRef CAS PubMed.
- C. K. Ryu, R. E. Park, M. Y. Ma and J. H. Nho, Bioorg. Med. Chem. Lett., 2007, 17, 2577 CrossRef CAS PubMed.
- J. Li, Y. F. Zhao, X. Y. Yuan, J. X. Xu and P. Gong, Molecules, 2006, 11, 574 CrossRef CAS.
- J. Sinkkonen, V. Ovcharenko, K. N. Zelenin, I. P. Bezhan, B. A. Chakchir, F. Al-Assar and K. Pihlaja, Eur. J. Org. Chem., 2002, 2046 CrossRef CAS.
- L. Zhang, L. P. Guan, X. Y. Sun, C. X. Wei, K. Y. Chai and Z. S. Quan, Chem. Biol. Drug Des., 2009, 73, 313 CAS.
- Y. Nomoto, H. Obase, H. Takai, M. Teranishi, J. Nakamura and K. Kubo, Chem. Pharm. Bull., 1990, 38, 2179 CrossRef CAS.
- N. Watanable, Y. Kabasawa, T. Takase, M. Matsukura, K. Miyazaki, H. Ishihara, K. Kodama and H. J. Adachi, J. Med. Chem., 1998, 41, 3367 CrossRef PubMed.
- H. Wu, X. M. Chen, Y. Wan, H. Q. Xin, H. H. Xu, R. Ma, C. H. Yue and L. L. Pang, Org. Lett., 2009, 6, 219 CrossRef CAS.
-
(a) R. Ghahremanzadeh, G. I. Shakibaei and A. Bazgir, Synlett, 2008, 1129 CAS;
(b) M. R. Nabid, S. J. T. Rezaei, R. Ghahremanzadeh and A. Bazgir, Ultrason. Sonochem., 2010, 17, 159 CrossRef CAS PubMed;
(c) R. Ghahremanzadeh, S. Ahadi, M. Sayyafi and A. Bazgir, Tetrahedron Lett., 2008, 49, 4479 CrossRef CAS PubMed;
(d) L. P. Liu, J. M. Lu and M. Shi, Org. Lett., 2007, 9, 1303 CrossRef CAS PubMed.
-
(a) M. Sayyafi, M. Seyyedhamzeh, H. R. Khavasi and A. Bazgir, Tetrahedron, 2008, 64, 2375 CrossRef CAS PubMed;
(b) G. Sabitha, C. Srinivas, A. Raghavendar and J. S. Yadav, Helv. Chim. Acta, 2010, 93, 1375 CrossRef CAS PubMed.
- L. Nagarapu, R. Bantu and H. B. Mereyala, J. Heterocycl. Chem., 2009, 46, 728 CrossRef CAS PubMed.
-
(a) H. R. Shaterian, M. Ghashang and M. Feyzi, Appl. Catal., A, 2008, 345, 128 CrossRef CAS PubMed;
(b) A. Hasaninejed, M. R. Kazerooni and A. Zare, Catal. Today, 2012, 96, 148 CrossRef PubMed.
- J. M. Khurana and D. Magoo, Tetrahedron Lett., 2009, 50, 7300 CrossRef CAS PubMed.
- H. R. Shaterian, F. Khorami, A. Amirzadeh, R. Doostmohammadi and M. Ghashang, J. Iran. Chem. Res., 2009, 2, 57 Search PubMed.
- H. R. Shaterian, A. Hosseinian and M. Ghashang, ARKIVOC, 2009, ii, 59 CrossRef.
- M. V. Reddy, R. G. C. Sekhar and Y. Tae Jeong, Tetrahedron, 2012, 68, 6820 CrossRef PubMed.
- H. Veisi, A. Aminimanesh, N. Khankhani and R. GHorbani Vaghei, RSC Adv., 2014, 4, 25057 RSC.
- S. Khaksar, S. M. Vahdat, M. Gholizadeh and S. M. Talesh, J. Fluorine Chem., 2012, 136, 8 CrossRef CAS PubMed.
- S. Khaksar and S. Mohammadizadeh Talesh, J. Fluorine Chem., 2012, 140, 95 CrossRef CAS PubMed.
- S. Khaksar, A. Heydari, M. Tajbaksh and S. M. Vahdat, J. Fluorine Chem., 2010, 131, 1377 CrossRef CAS PubMed.
-
(a) A review: I. A. Shuklov, N. V. Dubrovina and A. Borner, Synthesis, 2007, 2925 CrossRef CAS;
(b) A review: J. P. Bégué, D. Bonnet-Delpon and B. Crousse, Synlett, 2004, 18 Search PubMed.
- A. Hu, G. T. Yee and W. Lin, J. Am. Chem. Soc., 2005, 127, 12486 CrossRef CAS PubMed.
- M. Mojtahedi, M. S. Abaee and T. Alishiri, Tetrahedron Lett., 2009, 50, 2322 CrossRef CAS PubMed.
- M. Tajbakhsh, R. Hosseinzadeh, H. Alinezhad, S. Ghahari, A. Heydari and S. Khaksar, Synthesis, 2011, 490 CrossRef CAS PubMed.
- S. S. Minegishi, S. Kobayashi and H. Mayr, J. Am. Chem. Soc., 2004, 126, 5174 CrossRef CAS PubMed.
- A. Heydari, S. Khaksar and M. Tajbakhsh, Tetrahedron Lett., 2009, 50, 77 CrossRef CAS PubMed.
-
(a) B. Maleki, R. Tayebee, M. Kermanian and S. Sedigh Ashrafi, J. Mex. Chem. Soc., 2013, 57, 298 Search PubMed;
(b) B. Maleki and S. Sedigh Ashrafi, J. Mex. Chem. Soc., 2014, 58, 74 Search PubMed;
(c) B. Maleki and S. Sedigh Ashrafi, J. Mex. Chem. Soc., 2014, 58, 159 Search PubMed;
(d) B. Maleki, R. Tayebee, Z. Sepehr and M. Kermanian, Acta Chim. Slov., 2012, 59, 814 CAS;
(e) A. Mohammadi, H. Keshvari, R. Sandaroos, B. Maleki, H. Rouhi, H. Moradi, Z. Sepehr and S. Damavandi, Appl. Catal., A, 2012, 73, 429 Search PubMed;
(f) H. Veisi, B. Maleki, F. Hosseini Eshbala, H. Veisi, R. Masti, S. Sedigh Ashrafi and M. Baghayeri, RSC Adv., 2014, 4, 30683 RSC.
|
This journal is © The Royal Society of Chemistry 2014 |